An interventional study of Assessment of blood concentrations of microRNAs and Chemotherapy-induced peripheral neuropathy (CIPN) - grade in Cancer, Lung, Colon Neoplasm and Neuropathy;Peripheral, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's planned enrollment of 90 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients suffering from lung cancer and treated with paclitaxel
Diagnostic Test: Assessment of blood concentrations of microRNAs · Other: Chemotherapy-induced peripheral neuropathy (CIPN) - grade · Other: Pain assessement · Diagnostic Test: Assessment of blood concentrations of neurofilament light chain · Other: Neuropathic pain assessment · Other: Chemotherapy-induced peripheral neuropathy (CIPN) - severity
Patients suffering from colorectal cancer and treated with oxaliplatin
Diagnostic Test: Assessment of blood concentrations of microRNAs · Other: Chemotherapy-induced peripheral neuropathy (CIPN) - grade · Other: Pain assessement · Diagnostic Test: Assessment of blood concentrations of neurofilament light chain · Other: Neuropathic pain assessment · Other: Chemotherapy-induced peripheral neuropathy (CIPN) - severity
day 1, day 43, and day 155.
Also known as: MicroRNAs measured in patients' plasma.
day 1, day 43, and day 155.
Also known as: CIPN grade monitored using the National Cancer Institute - Common Terminology Criteria for Adverse Events.
day 1, day 43, and day 155.
Also known as: Pain assessment done with a numeric rating scale (scores from 0 (best) to 10 (worst)).
day 1, day 43, and day 155.
Also known as: Neurofilament light chain will measured in patients' plasma.
day 1, day 43, and day 155.
Also known as: Neuropathic pain assessed with the DN4 questionnaire, scores from 0 (best) to 7 (worst), and with a cut-off of 3 on 7 for neuropathic pain screening.
day 1, day 43, and day 155.
Also known as: CIPN severity assessed with the self-administered questionnaire QLQ-CIPN20 (scores from 0 (best) to 100 (worst)).
Blood concentrations of microRNAs and severity score of sensory chemotherapy-induced peripheral neuropathy
Concentrations of microRNAs will be assessed in plasma, and severity score of sensory chemotherapy-induced peripheral neuropathy will be assessed using the QLQ-CIPN20 questionnaire.
Time frame: day 1, day 43, and day 155
Grade of sensory chemotherapy-induced peripheral neuropathy
The grade of sensory chemotherapy-induced peripheral neuropathy will be assessed using the NCI-CTCAE v6.
Time frame: day 1, day 43, and day 155
Severity score of motor chemotherapy-induced peripheral neuropathy
The severity score of motor chemotherapy-induced peripheral neuropathy will be assessed using the QLQ-CIPN20 questionnaire
Time frame: day 1, day 43, and day 155
Pain occurrence and severity
Pain will be assessed using a numerical rating scale (0-10).
Time frame: day 1, day 43, and day 155
Occurrence of neuropathic pain
Neuropathic pain will be assessed in patients reporting pain with a numerical rating scale (NRS) score of 4 or higher out of 10, and a DN4 questionnaire (short form) score of 3 or higher out of 7.
Time frame: day 1, day 43, and day 155
Concentrations of neurofilament light chain
The concentration of neurofilament light chain will be assessed in plasma.
Time frame: day 1, day 43, and day 155
Plan to share: No — Due to French regulations, the data cannot be shared.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →